> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period for Amgen’s Aimovig
- URL: https://www.fdaweb.com/review-period-for-amgens-aimovig/
- Published: 2019-12-03T12:00:00.000Z
- Updated: 2026-09-14T15:55:08.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145627

*Federal Register* notice: FDA has determined for patent extension purposes the regulatory review period for Amgen’s Aimovig (erenumab-aooe), indicated for preventing migraines in adults. The regulatory review period is 2,042 days, which includes 1,675 days that occurred during the testing phase and 367 days during the approval phase. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2019-12-03/pdf/2019-26081.pdf?ref=fdaweb.com).